EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients

Lena Roth iD, Julian Stein, Peter E H Schwarz iD

Journal of Diabetes Research · 2025

DOI: 10.1155/jdr/6671361 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Research, 2025. Verfasst von Lena Roth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, tu-dresden.d…. Hauptthemen laut MEDLINE: Mobile Applications, Insulin, Hypoglycemic Agents, Glycemic Control. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Digital health interventions, such as mobile diabetes apps, are aimed at supporting glycemic control. Real‐world data (RWD) provide valuable insights into their long‐term effectiveness beyond the controlled conditions of randomized trials.

Objective

This study evaluates the effectiveness of the mobile diabetes app ESYSTA in improving glycemic control using real‐world evidence.

Methods

A retrospective analysis of 475 users was conducted to assess HbA1c changes after 6 months of usage and also long‐term usage (12 and 15 months). A linear mixed model was used to adjust for confounding factors.

Results

After 6 months, ESYSTA users achieved a significant HbA1c reduction of −0.59 (−0.70; −0.48) percentage points compared to baseline, which was maintained for up to 15 months. Users with higher baseline HbA1c showed greater reductions. Seventy‐five percent of users tracked their blood glucose values consistently during the whole observation period.

Conclusion

These real‐world evidence findings demonstrate the effectiveness of a mobile diabetes app in improving glycemic control over an extended period. While statistical adjustments addressed potential biases, missing data remain a challenge. Further research, including controlled studies, is needed to confirm these real‐world results and further explore the underlying mechanisms of sustained HbA1c improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mobile ApplicationsInsulinHypoglycemic AgentsGlycemic ControlDiabetes MellitusDiabetes Mellitus, Type 2HumansGlycated HemoglobinFemaleBlood GlucoseRetrospective StudiesMiddle AgedMaleDigital HealthAgedTelemedicineAdult

Stichwörter der Autor:innen

HbA1cdiabetes mellitusdigital health interventioneHealthreal-world datareal-world evidenceself-management

Substanzen

Glycated HemoglobinInsulinBlood GlucoseHypoglycemic Agentshemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department for Prevention and Care of Diabetes, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, tu-dresden.de.

ORCID-Profile: Lena Roth, Peter E H Schwarz

Zitieren

APA

Roth, L., Stein, J., & Schwarz, P. E. H. (2025). Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients. Journal of Diabetes Research. https://doi.org/10.1155/jdr/6671361

Vancouver

Roth L, Stein J, Schwarz PEH. Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients. Journal of Diabetes Research. 2025. doi:10.1155/jdr/6671361

BibTeX
@article{Roth2025,
  author = {Roth, Lena and Stein, Julian and Schwarz, Peter E H},
  title = {Real‐World Evidence on Mobile App–Supported Diabetes Management in Insulin‐Treated Patients},
  journal = {Journal of Diabetes Research},
  year = {2025},
  doi = {10.1155/jdr/6671361}
}
Kostenlos starten →